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HIGHLIGHTS 1 
- Few data are reported in literature regarding sepsis or septic shock due to ESBL strains. 2 
- The INCREMENT project is the largest international cohort study on ESBL infections.  3 
- Septic shock due to ESBL strains is associated with high 30-day mortality rate.  4 
- Escalation of antibiotic therapy is an important determinant of mortality. 5 
- Carbapenems should be used only in strains with resistance to ß-lactam/ß-lactamase inhibitors 6 
 7 
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Predictors of outcome in patients with severe sepsis or septic 8 
shock due to extended-spectrum β-lactamase-producing 9 
Enterobacteriaceae  10 
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ABSTRACT  99 
Purpose: Few data are reported in literature regarding severe sepsis or septic shock due 100 
to extended-spectrum β-lactamases (ESBL)-producing Enterobacteriaceae (E). The aim 101 
of this study was to assess predictors of outcome in septic patients with bloodstream 102 
infection (BSI) caused by ESBL-E. 103 
Methods: Patients with severe sepsis or septic shock and BSI due to ESBL-E were 104 
selected from the INCREMENT database. The primary endpoint of the study was the 105 
evaluation of predictors of outcome after 30 days from development of severe sepsis or 106 
septic shock due to ESBL-E infection. To perform analysis were created three cohorts: 107 
global, empirical-therapy and targeted-therapy cohorts. 108 
Results: 367 septic patients were analyzed. Overall mortality was 43.9% at 30 days; 109 
Escherichia coli (62.4%) and Klebsiella pneumoniae (27.2%) were the most frequent 110 
isolates. β-lactam/β-lactamase inhibitor (BLBLI) combinations was the most 111 
empirically used drug (43.6%), followed by carbapenems (29.4%); empirical therapy 112 
resulted active in vitro in 249 (67.8%) patients, but an escalation of antibiotic therapy 113 
was reported in 287 (78.2%) patients. Cox regression analysis showed that age, 114 
Charlson Comorbidity Index, McCabe classification, Pitt bacteremia score, abdominal 115 
source of infection and escalation of antibiotic therapy were independently associated 116 
with 30-day mortality. No differences were reported about survival in patients treated 117 
with BLBLI combinations or carbapenems in empirical or definitive therapy. 118 
Conclusions: BSI due to ESBL-E in patients who developed severe sepsis or septic 119 
shock was associated with high 30-day mortality; comorbidities, severity scores, source 120 
of infection and need of antibiotic therapy escalation were important determinants of 121 
unfavorable outcome.  122 
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INTRODUCTION 148 
Bloodstream infections (BSI) caused by extended-spectrum β-lactamases (ESBL)-149 
producing Enterobacteriaceae (E) are associated with high rates of treatment failure and 150 
increased mortality, especially when appropriate antimicrobial therapy is delayed [1-2-151 
3-4-5]. On this basis, the choice of an early effective empirical antibiotic therapy in 152 
critically ill patients with sepsis and/or septic shock is crucial to reduce the high rates of 153 
complications and unfavourable outcome [5].  154 
Previous publications resulting from the INCREMENT project [6-7-8-9-10] highlighted 155 
the necessity to identify peculiar clinical and therapeutic features of BSI due to ESBL 156 
strains. The role of carbapenems, considered the first choice for the treatment of severe 157 
infections caused by ESBL strains [11-12-13-14-15], was redefined also for the high 158 
incidence of carbapenem-resistant Enterobacteriaceae strains observed in the last few 159 
years [16]. On this basis, attention is now focused on promotion of carbapenem-sparing 160 
strategies and evaluation of efficacy of other drugs, like β-lactam/β-lactamase inhibitor 161 
combinations (BLBLI), that remain active against a considerable proportion of ESBL-E; 162 
however, the role of these drugs is controversial for the treatment of serious infections 163 
due to ESBL pathogens [17-18-19]. 164 
In this scenario, few data are reported in literature concerning sepsis or septic shock due 165 
to ESBL-E infections.  Thus, it is important for physicians to recognize peculiar clinical 166 
characteristics of sepsis or septic shock due to ESBL-E infections, to promptly identify 167 
patients at high risk of unfavorable outcome. Based on this scenario, the aim of this 168 
additional study from the INCREMENT project was to assess the predictors of outcome 169 
in septic patients with severe sepsis or septic shock caused by ESBL-producing strains. 170 
 171 
 172 
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MATERIALS AND METHODS 173 
Study Design and Patients 174 
The INCREMENT project is a retrospective international cohort study including 175 
patients with clinically significant BSI due to ESBL- or carbapenemase-producing 176 
Enterobacteriaceae from January 2004 to December 2013. Characteristics of the 177 
INCREMENT study were previously explained [15-16-17-18-19]. This analysis was 178 
reported according to the STROBE recommendations [20]. 179 
Patients with severe sepsis or septic shock and clinically significant BSI due to ESBL-E 180 
were selected from the original database. Data from patients were collected up to 30 181 
days after the diagnosis of BSI from charts; if needed, patients or relatives were 182 
contacted by phone.  183 
The INCREMENT project was approved by the Spanish Agency of Medicines 184 
(AEMPS; code JRB-ANT-2012-01) and the Hospital Universitario Virgen Macarena 185 
Institutional Review Board (code 1921); the need to obtain written informed consent 186 
was waived. Approval was also gained at participating centers according to local 187 
requirements.  188 
 189 
Variables, Microbiology and Definitions 190 
Data collected from all patients included: demographics, acquisition of infection, 191 
comorbidities by calculation of Charlson comorbidity index, McCabe classification, Pitt 192 
bacteremia score, source of BSI according to clinical and microbiological data, 193 
antimicrobial therapy, in vitro susceptibility to empirical and targeted antibiotic 194 
regimens, length of stay after BSI, and mortality.  195 
Enterobacteriaceae were identified using standard microbiological techniques in each 196 
participating center. ESBL-production was screened and confirmed according to CLSI 197 
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recommendations [21]; selected isolates from each center had been characterised by 198 
polymerase chain reaction (PCR) and DNA sequencing using established methods [17]. 199 
Nosocomial acquisition was considered when symptoms of infection started >48 hours 200 
after hospital admission or within 48 hours of hospital discharge, while we considered 201 
healthcare acquisition if patients had attended haemodialysis or received intravenous 202 
chemotherapy in the past 30 days, had been admitted to an acute-care hospital for at 203 
least 2 days or had surgery in the past 90 days, or resided in a nursing home or long-204 
term care facility. Other infections were considered community-acquired.  205 
For McCabe classification we used three categories: (1) non-fatal (mild and only a few 206 
comorbidities), (2) ultimately fatal (risk of death within four years or multiple 207 
comorbidities) and (3) rapidly fatal (risk of death during stay, intensive or terminal care 208 
patients) underlying diseases. 209 
Antimicrobial therapy administered before the susceptibility results were available was 210 
considered empirical; therapy administered after microbiological report was considered 211 
targeted/definitive.  212 
Severe sepsis was defined as sepsis with sepsis-induced organ dysfunction or tissue 213 
hypoperfusion (manifesting as hypotension, elevated lactate levels, or decreased urine 214 
output); septic shock as severe sepsis plus persistently low blood pressure following the 215 
administration of intravenous fluids [22]. 216 
Administered BLBLI were amoxicillin-clavulanate (AMC), piperacillin-tazobactam 217 
(PTZ), or ampicillin-sulbactam (AMS), quinolones were ciprofloxacin or levofloxacin, 218 
aminoglycosides were gentamicin or amikacin, while carbapenems included imipenem, 219 
meropenem, and ertapenem. Therapy was considered as monotherapy if no other drugs 220 
with intrinsic activity against gram-negative organisms were co-administered, 221 
irrespective of isolate susceptibility. 222 
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Active empirical therapy was considered the appropriateness of antibiotic therapy for all 223 
patients with an etiologic diagnosis according to susceptibility test criteria. We rated an 224 
antimicrobial treatment as inadequate if 1 or more of the organisms present were known 225 
to have intrinsic resistance or were found to be resistant through susceptibility testing. 226 
Escalation of antibiotic therapy was defined as the switch to or addition of a drug class 227 
or classes with a broader spectrum or additional coverage after 48 hours from the initial 228 
antibiotic therapy. 229 
 230 
Global, Empirical-therapy and Targeted-therapy cohorts 231 
We constructed 3 non-mutually exclusive cohorts to analyze predictors of mortality, 232 
including also therapeutic variables. The global cohort (GC) included all patients 233 
analyzed but were explored only pre-treatment variables to identify factors associated 234 
with mortality, irrespective of antibiotic therapies. The impact of empirical therapy was 235 
investigated in the empirical-therapy cohort (ETC), which included the patients who 236 
received a monotherapy that began within the first 24 h after blood cultures were taken 237 
and continued for at least 48 h (except for patients who died in ≤48 h, who were 238 
included if they received at least 1 complete day of therapy). The impact of targeted 239 
therapy was investigated in the targeted-therapy cohort (TTC), which included the 240 
patients who received a monotherapy once the susceptibility profile was available; the 241 
targeted drug must have started in ≤5 days and been administered for at least 50% of the 242 
total duration of therapy (except for patients who died while on targeted therapy, who 243 
were included if they received at least 1 complete day of therapy). 244 
 245 
Endpoints and Statistical Analysis 246 
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The primary endpoint of the study was the evaluation of predictors of outcome at 30 247 
days after development of septic shock due to ESBL infection. 248 
Separate analyses were performed for the three cohorts. To detect significant differences 249 
between groups, we used the chi-square test or Fisher exact test for categorical 250 
variables, and the 2-tailed t test or Mann-Whitney test for continuous variables, when 251 
appropriate. In univariate and multivariate analysis of survival, the Cox regression 252 
model was used to determine the effects of different variables on outcome at 30 days. 253 
The cumulative survival was evaluated using Kaplan-Meier product-limit estimators. 254 
The final multivariable Cox regression model was selected through forward stepwise 255 
regression based on Akaike Information Criterion.  256 
Statistical significance was established at ≤ 0.05. All reported P values are 2-tailed. The 257 
results were obtained using the statistical software R (version 3.3.4; Vienna, Austria).    258 
 259 
 260 
 261 
 262 
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 264 
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 270 
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 273 
RESULTS 274 
The INCREMENT database includes 1005 patients with BSI due to ESBL-E; out of 275 
these, 367 (36.5%) patients with severe sepsis or septic shock were analyzed. The 276 
number of cases per center in the global cohort ranged from 4 to 50 and wards of 277 
hospitalization at the time of ESBL-E isolation, in this study population, are reported in 278 
Figure 1.  279 
Baseline characteristics and comparison about clinical features of survivors and non-280 
survivors at 30 days are reported in Table 1. Overall, mortality at 30 days was observed 281 
in 161 (43.9%) patients. Comparison between the two patient groups showed that 282 
nosocomial acquisition of infection (64.5% Vs 50%, p=0.002), pneumonia (17.4% Vs 283 
8.3%, p=0.012), admission in ICU (32.2% Vs 18.9%, p=0.004), a higher Charlson 284 
Comorbidity index (3 points Vs 2 points, p=0.005), a higher Pitt bacteremia score (4 285 
points Vs 3 points, <0.001), need of NIV or MV (44% Vs 21.3%, p<0.001), and need of 286 
vasopressor agents (91.9% Vs 65%, p<0.001) were more frequently observed in non-287 
survivors. Conversely, a urinary source of infection (44.7 Vs 24.8, p<0.001) was more 288 
frequently reported in survivors, compared to patients with poor outcome. Finally, time 289 
to appropriate antibiotic therapy (4 days Vs 3 days, p=0.01) was longer in non-290 
survivors, compared to survivors. 291 
Etiologies of infection are described in Table 2. Overall, Escherichia coli (62.4%) and 292 
Klebsiella pneumoniae (27.2%) were the most frequent isolates; in vitro resistance to 293 
antibiotics prescribed in empirical therapy, was observed in 4/5 (80%) strains of 294 
Serratia marcescens, 23/29 (79.3%) of Enterobacter spp, 123/229 (53.7%) of 295 
Escherichia coli, and 41/100 (41%) of Klebsiella pneumoniae. Comparison between 296 
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survivors and non-survivors showed a more frequent isolation of Escherichia coli 297 
(67.5% Vs 55.9%, p=0.03) in survivors, while Klebsiella pneumoniae was more 298 
frequently isolated in non-survivors (34.2% Vs 21.8%, p=0.012), compared to 299 
survivors. 300 
Table 3 shows a comparison of antibiotics used in empirical and definitive regimens 301 
among survivors and non-survivors. BLBLI was the most empirically used class 302 
(43.6%), followed by carbapenems (29.4%), and cephalosporins (19.3%), while 303 
carbapenems (56.4%), and BLBLI (10.4%) were more frequently used as definitive 304 
therapy. A combination therapy was empirically used in 119 (32.4%) patients and in 93 305 
(25.3%) patients as definitive regimen. Empirical antibiotics resulted in vitro active in 306 
249 (67.8%) patients, and escalation of antibiotic therapy was used in 287 (78.2%) 307 
patients. Comparison between non-survivors and survivors showed that a carbapenem in 308 
definitive antibiotic regimen (42.9% Vs 67%, p<0.001) and a combination of antibiotics 309 
as definitive therapy (16.7% Vs 32%, p<0.001) were more frequently used in the latter.  310 
As reported in Table 4, univariate and multivariate Cox regression analysis about 311 
predictors of outcome at 30 days in the GC showed that age (HR 1.11, CI 95% 1.02-312 
1.22, p=0.021), McCabe classification (HR 1.39, CI 95% 1.12-1.72, p=0.003), Pitt 313 
bacteremia score (HR 1.14, CI 95% 1.09-1.19, p<0.001), and abdominal source of 314 
infection (HR1.66, CI 95% 1.08-1.89, p=0.02) were independently associated with 315 
death. 316 
Based on inclusion criteria (see Methods section), 31 patients were excluded from ETC 317 
and TTC to investigate the impact of therapy on 30-day mortality. 318 
The Table 5 shows that, at univariate and multivariate Cox regression analysis about 319 
predictors of outcome at 30 days in 106 patients of the ETC, McCabe classification (HR 320 
1.45, CI 95% 1.14-1.83, p=0.002), Pitt bacteremia score (HR 1.14, CI 95% 1.08-1.19, 321 
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p<0.001), and escalation of antibiotic therapy (HR 1.9, CI 95% 1.1-3.26, p=0.02) were 322 
independently associated with death. 323 
Univariate and multivariate Cox regression analysis about predictors of outcome at 30 324 
days in 230 patients of the TTC is reported in Table 6. Charlson Comorbidity Index 325 
(HR 1.20, CI 95% 1.11-1.30, p<0.001) and Pitt bacteremia score (HR 1.16, CI 95% 326 
1.09-1.24, p<0.001) were associated with death, while was reported a protective role for 327 
quinolones in definitive therapy (HR 0.29, CI 95% 0.11-0.8, p=0.016). 328 
Finally, Kaplan-Meier analysis of 30-day survival of patients in whom an escalation of 329 
antibiotic therapy was needed or not is reported in Figure 2. 330 
 331 
 332 
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 348 
 349 
 350 
 351 
DISCUSSION 352 
This study highlights the high mortality associated with BSI due to ESBL-E at 30 days 353 
from diagnosis in patients who developed severe sepsis or septic shock; furthermore, 354 
some clinical characteristics like source of infection (specifically from urinary tract, 355 
abdominal or pneumonia), indicators of severity (like comorbidities and admission in 356 
ICU), need of respiratory support and/or vasopressor agents were important 357 
determinants of outcome in this setting.  358 
However, Cox regression analysis identified age, McCabe classification, Charlson 359 
Comorbidity Index, Pitt bacteremia score, abdominal source of infection and escalation 360 
of antibiotic therapy (after microbiological report and/or worsening of clinical 361 
conditions) as factors independently associated with unfavourable outcome at 30 days. 362 
Finally, the use of a quinolone in definitive therapy was associated with 30-day 363 
survival. 364 
As previously reported in literature, the severity of clinical conditions (expressed by 365 
age, McCabe classification, Charlson Comorbidity Index and Pitt bacteremia score) at 366 
time of BSI onset plays a central role in determining the decreased survival in patients 367 
with infections due to ESBL-E [23]; furthermore, the progression to sepsis and septic 368 
shock is the crucial mechanism associated with high rates of mortality observed in this 369 
setting of critically ill patients with BSI due to ESBL strains [24-25-26]. Progression to 370 
septic shock may explain the apparently low effectiveness also of an adequate initial 371 
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antibiotic therapy, since septic shock is associated with a lethal cascade of events that is 372 
unlikely to be interrupted even by an appropriate initial antimicrobial treatment. In 373 
addition, most of our patients were severely ill and would probably have been unable to 374 
survive their infections independently of the administration of an adequate initial 375 
antimicrobial treatment. Finally, the lack of homogeneity in management and treatment 376 
of septic patients could partly explain the high rates of mortality. 377 
Of importance, the need of an antibiotic therapy escalation after microbiological report 378 
and/or worsening of clinical conditions was independently associated with unfavourable 379 
outcome at 30 days, confirming previous observations about an initial inadequate 380 
antimicrobial treatment as a major risk factor for mortality [27]. Moreover, severe 381 
infections could have an unfavorable outcome despite the administration of adequate 382 
antimicrobial treatment, due to the inability to raise plasma drug concentrations above 383 
the target MIC. This latter finding may be the cause of underexposure at the infection 384 
site, especially in critically ill patients, since septic patients usually require rapid and 385 
aggressive fluid resuscitation therapy with a subsequent increase in the extracellular 386 
ﬂuid volume that could raise the volume of distribution of drugs [28]. On this basis, 387 
differences in rates of mortality could be related to the source of bacteremia. Several 388 
studies demonstrated a relationship between source of infection and clinical response 389 
[29], with bacteremia secondary to urinary tract infection usually associated with the 390 
lowest mortality rate [30]. In our population, as previously reported in literature [29], 391 
the abdominal source of infection was an independent determinant of unfavorable 392 
outcome considering the abovementioned observations.  393 
An important finding of this analysis was the impact of empirical and definitive 394 
antibiotic regimens on 30-day outcome, especially for patients treated with carbapenem 395 
or BLBLI. The spread of carbapenemase-producing Enterobacteriaceae promoted 396 
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several studies about alternative therapies, like BLBLI. BLBLI has been evaluated for 397 
the treatment of these infections [18-31], but no definitive data were reported about the 398 
efficacy of BLBLI in the treatment of severe infections, when compared to carbapenems 399 
[14-32]. On this basis, the use of carbapenems should be optimized, recommending a 400 
role as empirical therapy only for patients who have high risk factors for 401 
colonization/infection, based also on geographical patterns of resistance about ESBL 402 
strains not susceptible to BLBLI, and on patients who are affected by non-urinary 403 
source of bacteremia [33]. In the remaining subjects, in whom clinical conditions or risk 404 
factors may not require immediate ESBL antimicrobial coverage, a guided therapy once 405 
culture results are obtained may be sufficient [ 34 ]. For these reasons, data from 406 
international trials will have to assess 30-day mortality associated with the use of 407 
BLBLI or carbapenems in the setting of ESBL infections [35]. Of interest, in our 408 
analysis quinolones resulted as protective in definitive therapy. The explanation is that, 409 
when active in vitro, quinolones were a reasonable choice in less critically-ill patients 410 
with urinary source of infection. The interpretation of this data is limited by the 411 
retrospective design of the study and only randomized trials could address a possible 412 
role of quinolones, also in severe infections. However, their use should be carefully 413 
evaluated considering the high rates of resistance reported, especially in area with an 414 
increased consumption of these antibiotics [36-37]. 415 
Of importance, the retrospective nature of the study is a limitation and all the 416 
considerations about the impact of empirical or targeted regimens on survival should be 417 
done with caution. Nevertheless, our series of septic shock associated with ESBL-E 418 
bacteremia is the largest ever reported in literature. Another study limitation is the lack 419 
of information of other variables that may influence the outcome, such as source 420 
control, circulatory management and PK/PD variables. Finally, no data were recorded 421 
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on long-term survival over 30 days; thus, we cannot provide more consistent 422 
information on the risk of recurrence of infection and emergence of resistant strains to 423 
antibiotic regimen used. However, in the database were applied very strict criteria for 424 
the cataloguing of antibiotic regimens and an important strength of this study is the 425 
multicenter and international participation to INCREMENT project, with collection of 426 
data from different countries. 427 
 428 
CONCLUSIONS 429 
In conclusion, these data point out the high 30-day mortality associated with BSI due to 430 
ESBL-E in patients who developed severe sepsis or septic shock, together with the 431 
importance of some clinical characteristics, like source of infection and indicators of 432 
severity, as determinants of patient’s outcome in this setting, requiring an early 433 
escalation of antibiotic therapy. Moreover, these data confirm no differences in 434 
empirical and definitive antibiotic therapy of BSI, especially for BLBLI and 435 
carbapenems, in these critically ill patients. However, randomized clinical trials are 436 
needed to confirm these observations. 437 
 438 
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Figure 1. Wards of hospitalization at time of ESBL-E isolation  484 
 485 
Legend. ESBL-E: extended-spectrum beta-lactamases-producing Enterobacteriaceae. 486 
 487 
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Figure 2. Kaplan-Meier curves about 30-day survival of patients in which 488 
was needed or not an escalation of antibiotic therapy* 489 
 490 
*p<0.001 491 
 492 
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Table 1. Comparison about baseline characteristics and clinical features of 493 
survivors and non-survivors at 30 days in the global cohort 494 
 
Variables 
 
All patients 
N=367 (%) 
 
Survivors 
N=206 (%) 
 
Non-Survivors 
N=161 (%) 
 
p 
Age, median (IQR) 69 (57-78) 68 (56-77) 70 (57-80) 0.30 
Male sex 216 (58.9) 127 (61.7) 89 (55.3) 0.26 
Acquisition of infection 
             Community  
             Healthcare 
             Nosocomial 
 
46 (12.5) 
106 (28.9) 
207 (56.4) 
 
30 (14.5) 
70 (33.9) 
103 (50) 
 
16 (9.9) 
36 (22.3) 
104 (64.5) 
 
0.26 
0.01 
0.002 
Source of infection 
            Primary BSI 
            Urinary  
            Biliary  
            SSTI 
            Abdominal 
            Pneumonia 
            Osteoarticular 
            CNS 
            Other 
 
22 (6) 
132 (36) 
36 (9.8) 
7 (1.9) 
50 (13.6) 
45 (12.3) 
2 (0.5) 
1 (0.3) 
93 (25.3) 
 
10 (4.9) 
92 (44.7) 
23 (11.2) 
4 (1.9) 
22 (10.7) 
17 (8.3) 
2 (1) 
0 
60 (29.1) 
 
12 (7.5) 
40 (24.8) 
13 (8.1) 
3 (1.9) 
28 (17.4) 
28 (17.4) 
0 
1 (0.6) 
33 (20.4) 
 
0.41 
<0.001 
0.42 
1.0 
0.09 
0.012 
0.59 
0.90 
0.085 
McCabe classification, nonfatal 145 (39.5) 97 (47) 48 (29.8) <0.001 
Charlson Comorbidity Index, median 
(IQR) 
3 (1-5) 2 (0-4) 3 (2-8) 0.005 
Pitt bacteremia score, median (IQR) 3 (2-5) 3 (1-4) 4 (2-7) <0.001 
Comorbidities 
            Diabetes 
            COPD 
            Myocardial infarct 
            Congestive heart failure 
            Peripheral arterial disease 
            Dementia 
            Immunological disease 
            Ulcerative disease 
            Liver disease 
            Kidney disease 
            Cancer 
            Neurological disease 
            AIDS 
 
124 (33.8) 
77 (21) 
47 (12.8) 
70 (19.1) 
40 (10.9) 
41 (11.2) 
16 (4.4) 
23 (6.3) 
58 (15.8) 
84 (22.9) 
148 (40.3) 
77 (21) 
8 (2.2) 
 
60 (29.1) 
37 (17.9) 
20 (9.7) 
31 (15) 
16 (7.8) 
22 (10.7) 
9 (4.3) 
12 (5.8) 
31 (15) 
41 (19.9) 
88 (42.7) 
36 (17.4) 
6 (2.9) 
 
64 (39.7) 
40 (24.8) 
27 (16.7) 
39 (24.2) 
24 (14.9) 
19 (11.8) 
7 (4.3) 
11 (11.1) 
27 (16.7) 
43 (26.7) 
60 (37.2) 
41 (25.4) 
2 (1.2) 
 
0.027 
0.09 
0.12 
0.027 
0.046 
0.83 
1.0 
0.81 
0.68 
0.12 
0.43 
0.08 
0.47 
ICU admission 91 (24.8) 39 (18.9) 52 (32.2) 0.004 
Need of NIV or MV 115 (31.3) 44 (21.3) 71 (44) <0.001 
Need of vasopressor agents 282 (76.8) 134 (65) 148 (91.9) <0.001 
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Legend. IQR: inter-quartile range; BSI: bloodstream infection; SSTI: skin and soft tissue infection; CNS: 495 
central nervous system; COPD: chronic obstructive pulmonary disease; AIDS: acquired immune 496 
deficiency syndrome; ICU: intensive care unit; NIV: non-invasive mechanical ventilation; MV: 497 
mechanical ventilation. 498 
 499 
 500 
Table 2. Etiology of infection among survivors and non-survivors at 30 501 
days and rate of resistance to empirical therapy 502 
Pathogens Survivors 
N=206 (%) 
Non-Survivors 
N=161 (%) 
p Resistance to empirical therapy 
N° resistant isolates/ total isolates (%) 
Escherichia coli 139 (67.5) 90 (55.9) 0.03 123/229 (53.7) 
Klebsiella pneumoniae 45 (21.8) 55 (34.2) 0.012 41/100 (41) 
Enterobacter spp 17 (8.3) 12 (7.5) 0.93 23/29 (79.3) 
Serratia marcescens 3 (1.5) 2 (1.2) 1.0 4/5 (80) 
Proteus spp 0 2 (1.2) 0.37 0 
Citrobacter spp 1 (0.5) 0 1.0 0 
Morganella morganii 1 (0.5) 0 1.0 0 
 503 
Table 3. omparison between antibiotics administered in empirical and 504 
definitive therapy to survivors and non-survivors at 30 days in the global 505 
cohort 506 
 
Antibiotics 
 
Empirical therapy Definitive therapy 
Survivors 
N=206 (%) 
Non-Survivors 
N=161 (%) 
 
p 
Survivors 
N=206 (%) 
Non-Survivors 
N=161 (%) 
 
p 
Cephalosporin 43 (20.9) 28 (17.4) 0.48 3 (1.5) 1 (0.6) 0.80 
BLBLI 94 (45.6) 66 (41) 0.43 27 (13.1) 11 (6.8) 0.07 
Time to appropriate antibiotic therapy, 
days, median (IQR)  
3 (1-5) 3 (1-4) 4 (2-5) 0.01 
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Aminoglycosides 22 (10.7) 21 (13) 0.59 16 (7.8) 8 (5) 0.39 
Quinolones 30 (14.6) 25 (15.5) 0.91 14 (6.8) 6 (3.7) 0.29 
TMP/SMX 1 (0.5) 0 1.0 8 (3.9) 4 (2.5) 0.65 
Fosfomycin 2 (1) 0 0.59 0 0 - 
Tetracycline 2 (1) 2 (1.2) 1.0 0 0 - 
Monobactams 1 (0.5) 1 (0.6) 1.0 0 0 - 
Colistin 1 (0.5) 1 (0.6) 1.0 3 (1.5) 1 (0.6) 0.79 
Carbapenem 61 (29.6) 47 (29.2) 0.44 138 (67) 69 (42.9) <0.001 
Tigecycline 0 0 - 6 (2.9) 2 (1.2) 0.47 
Chloramphenicol 0 0 - 1 (0.5) 0 1.0 
Combination therapy 150 (72.8) 111 (68.9) 0.54 88 (42.7) 49 (30.4) 0.001 
Median length of therapy (IQR) 3 (1-4) 2 (1-4) 0.1 11 (5-14) 7 (3-10) <0.001 
Active empirical therapy 143 (69.4) 106 (65.8) 0.54  
Escalation of antibiotic therapy 154 (74.7) 133 (82.6) 0.09 
Legend. BLBLI: ß-lactam/ß-lactamase inhibitor; TMP/SMX: Trimethoprim/sulfamethoxazole: IQR: 507 
inter-quartile range. 508 
Note. BLBLI: amoxicillin/clavulanate or ampicillin/sulbactam or piperacillin-tazobactam 509 
Quinolones: ciprofloxacin or levofloxacin 510 
Aminoglycosides: gentamicin or amikacin 511 
Carbapenem: meropenem or imipenem or ertapenem 512 
 513 
Table 4. Univariate and Multivariate Cox regression analysis about 514 
predictors of outcome at 30 days in 367 patients of the global cohort 515 
 516 
 
VARIABLES 
 
UNIVARIATE 
 
MULTIVARIATE 
 HR 95%CI p HR 95%CI p 
Age 1.1 1.01-1.21 0.031 1.11 1.02-1.22 0.021 
Male sex 0.84 0.62-1.15 0.284    
Acquisition of infection 
             Healthcare 
             Nosocomial 
 
0.95 
1.38 
 
0.53-1.71 
0.81-2.34 
 
0.863 
0.233 
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Source of infection 
            Primary BSI 
            Urinary 
            Biliary 
            SSTI 
            Abdominal 
            Pneumonia 
 
1.08 
0.59 
0.81 
0.82 
1.46 
0.45 
 
0.6-1.94 
0.41-0.84 
0.46-1.44 
0.26-2.57 
0.97-2.19 
1.04-2.36 
 
0.807 
0.003 
0.478 
0.735 
0.07 
0.3 
 
 
 
 
 
1.66 
 
 
 
 
 
 
1.08-1.89 
 
 
 
 
 
 
0.02 
 
ICU admission 1.4 1.01-1.95 0.047    
Charlson Comorbidity Index 1.05 0.99-1.11 0.083    
McCabe classification 1.54 1.25-1.89 <0.001 1.39 1.12-1.72 0.003 
Pitt bacteremia score 1.14 1.09-1.19 <0.001 1.14 1.09-1.19 <0.001 
Comorbidities 
            Diabetes 
            COPD 
            Myocardial infarct 
            Congestive heart failure 
            Peripheral arterial disease 
            Dementia 
            Immunological disease 
            Ulcerative disease 
            Liver disease 
            Kidney disease 
            Cancer 
 
1.42 
1.28 
1.29 
1.28 
1.41 
1.08 
0.82 
1.08 
1.11 
1.31 
0.85 
 
1.03-1.95 
0.89-1.84 
0.85-1.96 
0.87-1.84 
0.91-2.18 
0.67-1.75 
0.39-1.76 
0.58-1.99 
0.73-1.68 
0.92-1.87 
0.62-1.18 
 
0.033 
0.175 
0.238 
0.19 
0.12 
0.752 
0.617 
0.816 
0.629 
0.132 
0.334  
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            AIDS 0.43 0.11-1.72 0.232 
Need of NIV or MV 1.93 1.4-2.64 <0.001    
Need of vasopressor agents 1.37 1.01-2.08 0.044    
Legend. HR: hazard ratio; CI: confidence interval; BSI: bloodstream infection; SSTI: skin and soft tissue 517 
infection; ICU: intensive care unit; COPD: chronic obstructive pulmonary disease; AIDS: acquired 518 
immune deficiency syndrome; NIV: non-invasive mechanical ventilation; MV: mechanical ventilation. 519 
 520 
Table 5. Univariate and Multivariate Cox regression analysis about 521 
predictors of outcome at 30 days in 106 patients of the empirical-therapy 522 
cohort 523 
 524 
 
VARIABLES 
 
UNIVARIATE 
 
MULTIVARIATE 
 HR CI 95% p HR CI 95% p 
Age  1.09 0.99-1.19 0.075    
Male sex 0.82 0.59-1.13 0.226    
Acquisition of infection 
             Healthcare 
             Nosocomial 
 
0.95 
1.36 
 
0.52-1.74 
0.79-2.35 
 
0.861 
0.270 
   
Source of infection 
            Primary BSI 
            Urinary  
            Biliary  
            SSTI 
            Abdominal 
            Pneumonia 
 
1.19 
0.56 
0.87 
0.85 
1.42 
1.79 
 
0.66-2.15 
0.39-0.82 
0.49-1.54 
0.27-2.68 
0.93-2.17 
1.18-2.72 
 
0.562 
0.003 
0.639 
0.786 
0.104 
0.006 
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ICU admission 1.58 1.12-2.23 0.009    
Charlson Comorbidity Index 1.06 0.99-1.12 0.069    
McCabe classification 1.55 1.25-1.93 <0.001 1.45 1.14-1.83 0.002 
Pitt bacteremia score 1.16 1.11-1.22 <0.001 1.14 1.08-1.19 <0.001 
Comorbidities 
            Diabetes 
            COPD 
            Myocardial infarct 
            Congestive heart failure 
            Peripheral arterial disease 
            Dementia 
            Immunological disease 
            Ulcerative disease 
            Liver disease 
            Kidney disease 
            Cancer 
            AIDS 
 
1.37 
1.45 
1.43 
1.43 
1.25 
0.98 
0.79 
1.09 
1.12 
1.43 
0.91 
0.44 
 
0.98-1.92 
1.01-2.1 
0.92-2.21 
0.98-2.09 
0.77-2.03 
0.58-1.65 
0.35-1.80 
0.57-2.07 
0.73-1.73 
0.99-2.05 
0.65-1.27 
0.11-1.78 
 
0.062 
0.047 
0.111 
0.06 
0.357 
0.934 
0.58 
0.797 
0.593 
0.056 
0.578 
0.249 
   
Need of NIV or MV 1.96 1.41-2.72 <0.001    
Need of vasopressor agents 1.69 1.14-2.49 0.008    
Cephalosporin 0.87 0.57-1.31 0.494    
BLBLI 0.95 0.69-1.32 0.763    
Aminoglycosides 1.06 0.67-1.68 0.808    
Quinolones 1.12 0.73-1.73 0.595    
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Tetracycline 1.34 0.33-5.44 0.677    
Carbapenem 1.02 0.72-1.44 0.914    
Combination therapy 0.78 0.65-1.11 0.12    
Escalation of antibiotic therapy  1.92 1.12-3.28 0.017 1.9 1.1-3.26 0.02 
Time to appropriate antibiotic 
therapy 
1.2 0.87-2.34 0.25 
   
Legend. HR: hazard ratio; CI: confidence interval; BSI: bloodstream infection; SSTI: skin and soft tissue 525 
infection; ICU: intensive care unit; COPD: chronic obstructive pulmonary disease; AIDS: acquired 526 
immune deficiency syndrome; NIV: non-invasive mechanical ventilation; MV: mechanical ventilation. 527 
 528 
Table 6. Univariate and Multivariate Cox regression analysis about 529 
predictors of outcome at 30 days in 230 patients of the targeted-therapy 530 
cohort 531 
 532 
 
VARIABLES 
 
UNIVARIATE 
 
MULTIVARIATE 
 HR CI 95% p HR CI 95% p 
Age 1.1 1.01-1.21 0.031    
Male sex 1.19 0.62-1.15 0.284    
Acquisition of infection 
             Healthcare 
             Nosocomial 
 
0.95 
1.38 
 
0.53-1.72 
0.81-2.34 
 
0.863 
0.233 
   
Source of infection 
            Primary BSI 
            Urinary  
            Biliary  
 
1.73 
0.68 
1.53 
 
0.79-3.76 
0.41-1.13 
0.79-2.99 
 
0.169 
0.137 
0.208 
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            SSTI 
            Abdominal 
            Pneumonia 
1.71 
0.92 
1.52 
0.54-5.41 
0.44-1.92 
0.87-2.68 
0.365 
0.829 
0.144 
ICU admission 1.4 1.01-1.95 0.047    
Charlson Comorbidity Index 1.05 0.99-1.11 0.083 1.20 1.11-1.30 <0.001 
McCabe classification 1.54 1.25-1.89 <0.001    
Pitt bacteremia score 1.14 1.09-1.19 <0.001 1.16 1.09-1.24 <0.001 
Comorbidities 
            Diabetes 
            COPD 
            Myocardial infarct 
            Congestive heart failure 
            Peripheral arterial disease 
            Dementia 
            Immunological disease 
            Ulcerative disease 
            Liver disease 
            Kidney disease 
            Cancer 
            AIDS 
 
1.42 
1.29 
1.29 
1.28 
1.41 
1.08 
0.66 
1.08 
1.11 
1.31 
0.85 
0.43 
 
1.03-1.95 
0.89-1.84 
0.85-1.96 
0.89-1.84 
0.91-2.18 
0.67-1.75 
0.21-2.09 
0.58-1.99 
0.73-1.68 
0.92-1.87 
0.62-1.18 
0.11-1.72 
 
0.033 
0.175 
0.238 
0.19 
0.12 
0.752 
0.475 
0.816 
0.629 
0.132 
0.334 
0.232 
   
Need of NIV or MV 1.88 1.18-3.0 0.008    
Need of vasopressor agents 1.32 0.79-2.18 0.287    
Cephalosporin 1.46 0.1-4.91 0.708    
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BLBLI 1.64 0.33-1.13 0.114    
Aminoglycosides 0.59 0.29-1.20 0.142    
Quinolones 0.54 0.24-1.22 0.141 0.29 0.11-0.8 0.016 
TMP/SMX 1.01 0.32-3.19 0.992    
Colistin 0.5 0.07-3.61 0.493    
Carbapenem 0.96 0.54-1.71 0.883    
Tigecycline 0.3 0.04-2.2 0.239    
Combination therapy 0.59 0.39-1.22 0.24    
Legend. HR: hazard ratio; CI: confidence interval; BSI: bloodstream infection; SSTI: skin and soft tissue 533 
infection; ICU: intensive care unit; COPD: chronic obstructive pulmonary disease; AIDS: acquired 534 
immune deficiency syndrome; NIV: non-invasive mechanical ventilation; MV: mechanical ventilation. 535 
 536 
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